Approach to Validating an Opsonophagocytic Assay for Streptococcus pneumoniae
Open Access
- 1 February 2005
- journal article
- research article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 12 (2) , 287-295
- https://doi.org/10.1128/cdli.12.2.287-295.2005
Abstract
Streptococcus pneumoniae (pneumococcus) polysaccharide serotype-specific antibodies that have opsonophagocytic activity are considered a primary mechanism of host defense against pneumococcal disease. In vitro opsonophagocytic assays (OPAs) with antibody and complement to mediate opsonophagocytic killing of bacteria have been designed and developed as an adjunct to the standardized serum immunoglobulin G antipneumococcal capsular polysaccharide enzyme immunoassay to assess the effectiveness of pneumococcal vaccines. OPA presents challenges for assay standardization and assay precision due to the multiple biologically active and labile components involved in the assay, including human polymorphonuclear leukocytes or cultured effector cells, bacteria, and complement. Control of these biologically labile components is critical for consistent assay performance. An approach to validating the performance of the assay in accordance with International Conference for Harmonization guidelines, including its specificity, intermediate precision, accuracy, linearity, and robustness, is presented. Furthermore, we established parameters for universal reagents and standardization of the use of these reagents to ensure the interlaboratory reproducibility and validation of new methodologies.Keywords
This publication has 36 references indexed in Scilit:
- Multilaboratory Evaluation of a Viability Assay for Measurement of Opsonophagocytic Antibodies Specific to the Capsular Polysaccharides of Streptococcus pneumoniaeClinical and Vaccine Immunology, 2003
- Enzyme-Linked Immunosorbent Assay for Quantitation of Human Antibodies to Pneumococcal PolysaccharidesClinical and Vaccine Immunology, 2003
- Functional Antibodies Elicited by an 11‐Valent Diphtheria–Tetanus Toxoid–Conjugated Pneumococcal VaccineThe Journal of Infectious Diseases, 2003
- Specificities and Opsonophagocytic Activities of Antibodies to Pneumococcal Capsular Polysaccharides in Sera of Unimmunized Young ChildrenClinical and Vaccine Immunology, 2002
- Prevention of pneumococcal disease in children. Pneumococcal conjugate vaccines: their use globally could have a major impact on public healthActa Paediatrica, 2001
- Comparison of a Classical Phagocytosis Assay and a Flow Cytometry Assay for Assessment of the Phagocytic Capacity of Sera from Adults Vaccinated with a Pneumococcal Conjugate VaccineClinical and Diagnostic Laboratory Immunology, 2001
- Pneumococcal Type 22F Polysaccharide Absorption Improves the Specificity of a Pneumococcal-Polysaccharide Enzyme-Linked Immunosorbent AssayClinical and Diagnostic Laboratory Immunology, 2001
- Commitment of Neutrophilic Differentiation and Proliferation of HL-60 Cells Coincides with Expression of Transferrin ReceptorJournal of Biological Chemistry, 1999
- Pathogenesis of Pneumococcal InfectionNew England Journal of Medicine, 1995
- Acute respiratory infections in the developing worldThe Pediatric Infectious Disease Journal, 1987